Actively Recruiting
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-11-25
30
Participants Needed
4
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
CONDITIONS
Official Title
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed Informed Consent Form available
- Age between 18 and 75 years at time of consent
- Diagnosis of hepatocellular carcinoma confirmed by histology
- Initially resectable hepatocellular carcinoma with high-risk recurrence features such as tumor size over 5 cm, more than 3 tumors, vascular invasion, or poor tumor differentiation (Grade 3 or 4)
- Measurable disease with at least one target lesion according to RECIST v1.1
- Child-Pugh A liver function status
- ECOG performance status 0 to 1
- No prior locoregional or systemic treatment for hepatocellular carcinoma
- Negative HIV test at screening
You will not qualify if you...
- Known fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, mixed cholangiocarcinoma, recurrent or diffuse hepatocellular carcinoma
- Clinically diagnosed hepatic encephalopathy within the last 6 months
- Autoimmune hepatitis requiring liver biopsy
- History of organ transplantation
- Clinical symptoms of pleural effusion, ascites, pericardial effusion, or history of kidney disease or nephrotic syndrome
- Treatment with investigational therapy within 28 days prior to study treatment
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk of bleeding
- Prior bleeding event from esophageal and/or gastric varices within 6 months before study treatment
- Known severe allergic reaction to contrast agents (e.g., anaphylaxis)
- Pregnancy or breastfeeding
- Inability to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
2
Henan Cancer Hospital
Zhengzhou, Henan, China
Not Yet Recruiting
3
The First Hospital of China Medical University
Shenyang, Liaoning, China
Not Yet Recruiting
4
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
Not Yet Recruiting
Research Team
X
Xinyu Bi
CONTACT
X
Xiaowu Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here